Tag: Ignyta Inc.

Ignyta Chief Medical Officer Pratik Mutani MD

STARTRK-2: A Basket Trial for Neuroendocrine Tumor Patients with Specific Gene Rearrangements

April 7, 2017

Precision medicine, molecular testing, basket studies, STARTRK-2 – it may sound like technology of the future but it is here today and it might be the answer to slowing or stopping tumor growth for neuroendocrine tumor (NET) patients who have specific…

READ MORE